Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2019 16:01 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update

SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2019...
August 12, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing...
August 08, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the presentation of a poster at the upcoming annual meeting...
August 06, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
July 22, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition

DARE-HRT1 is a potential treatment of menopause-related symptoms DARE-FRT1 is a potential pregnancy maintenance therapy SAN DIEGO, July 22, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc....
July 17, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model

SAN DIEGO, July 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has received notification from the American...
July 15, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors

SAN DIEGO, July 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced today that William H. Rastetter, Ph.D., a current member of its...
June 26, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®

SAN DIEGO, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its...
June 17, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

SAN DIEGO, June 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to...
May 29, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience to Present at the 2019 BIO International Convention

SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right